Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

NASH Drug Pipeline & Market Overview, 2020 - Almost 80 Drug Candidates Involved - ResearchAndMarkets.com

February 11, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Feb 11, 2020--

The “NASH Drug Pipeline and Market Overview” report has been added to ResearchAndMarkets.com’s offering.

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate.

In addition, the report provides the following data:

In creating its market forecast, the analyst discusses the indicators that needed to be evaluated to create this estimate, commenting on:

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: NASH

Chapter 3: Products in Development

Chapter 4: Market Opportunity

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/gv65fi

View source version on businesswire.com:https://www.businesswire.com/news/home/20200211005771/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 02/11/2020 11:18 AM/DISC: 02/11/2020 11:18 AM